APR 22, 2025

Boosting Bispecific Antibody Yields with >98% Purity

WRITTEN BY: Sarah Hoffman

Bispecific antibodies (bsAbs) are shaping the future of therapeutics, but challenges like limited throughput, low yields, and chain mispairing across diverse formats can slow progress.

This white paper shares practical strategies and real-world case studies to help you tackle these hurdles. Discover how optimized production methods can deliver better results, even for the most complex bsAb formats.

Download the white paper to explore: